ADHD (dysregulated attention)

To be able to sit still, pay attention, and occasionally control one’s impulses can be difficult for almost everybody. The condition commonly known as Attention-deficit/hyperactivity disorder (ADHD) is a growing behavioral diagnosis for children and adults, and has become one of the main targets of modern health care.
The application of Neurofeedback technology offers an evidence-based and clinically tested opportunity to bring relief from ADHD, both for children and adults. The ability to measure and then reinforce specific EEG (electroencephalogram) activity of the brain allows neurofeedback to target the very source of ADHD symptoms.

Over six million children, and three million adults in the US report struggling with symptoms of ADHD in their home, professional, academic, and social lives

38% of adults with primary diagnosis of ADHD report clinical mood disorders

Studies show that a Learning Disorder (LD) is present in 70% of children with ADHD

Depressive disorders in youth with ADHD show up five times higher than in youth without ADHD

Nearly half of individuals who take ADHD medication report side effects such as, sleep disorders, low appetite, weight loss, or social withdrawal

Affects males more than females

Research on ADHD over the past 20+ years shows:

Brain wave (EEG) analyses show that ADHD is typically characterized by dysregulation of either fronto-central Theta or Beta activity

The “theta/beta ratio” earned the Food and Drug Administration’s (FDA) approval as a diagnostic marker of ADHD

The effects of ADHD medication on human physiology is often associated with poor sleep and appetite, resulting in decrease in body weight and height of children in as little as 3 years of use

The average cost for behavior therapy for ADHD is around $11,000.00 per case, while neurofeedback often averages between $3000-$5000 per case

The inclusion criteria for diagnosis ADHD is so broad, that it often leads to a misdiagnosis and eventual misuse of treatment options

Original research on the sensorimotor rhythm of 12-15Hz (SMR) has shown that its reinforcement with neurofeedback is associated with improved executive function and reduction if ADHD symptoms

Neurofeedback reinforces healthy brain performance

Neurofeedback uses QEEG imaging technology to identify specific markers of ADHD, and its subtypes

Joel Lubar, Ph.D. and colleagues pioneered research in identifying that the "theta-beta" brainwave ratio discrepancy had up to a 91% diagnostic validity of ADHD

A large meta-analysis of ten separate studies on neurofeedback found that the effects of brain training lasted up to 12 months after the completion of the treatmen

EEG research in co-occurring sleep disorders that are common in ADHD cases show the same theta and beta ratios biomarker

In October 2012 the American Academy of Pediatrics ranked neurofeedback to the highest level of evidence-based support for the treatment of ADHD

The application of QEEG results allows more precise targeting of neurofeedback to the brain areas associated with each specific ADHD subtype marker

The advancement of neurofeedback signals a future where peak mental health and cognitive function transcend genetic and environmental constraints, becoming accessible to all, akin to contemporary healthcare. This brings immense hope to those grappling with attentional dysregulation. The capacity to condition and direct specific brain processes offers unprecedented control, exerting a profound impact on individual cognitive performance and overall health. This transformative potential signifies a paradigm shift in mental wellness, promising inclusivity and empowerment for individuals seeking enhanced cognitive capabilities.

References: